Literature DB >> 11250876

[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man.

S D Katugampola1, J J Maguire, S R Matthewson, A P Davenport.   

Abstract

1. We have determined the binding characteristics of [(125)I]-(Pyr(1))Apelin-13, a putative ligand for the APJ orphan receptor in human cardiovascular and rat tissue and investigated the functional properties of (Pyr(1))Apelin-13 in human saphenous vein. 2. The binding of [(125)I]-(Pyr(1))Apelin-13 to sections of human heart tissue was time dependent and rapid at 23 degrees C. Data were fitted to a single site model with an association rate constant (k(obs)) of 0.115 min(-1). [(125)I]-(Pyr(1))Apelin-13 also dissociated from a single site with a dissociation rate constant of 0.0105 min(-1). 3. In saturation binding experiments [(125)I]-(Pyr(1))Apelin-13 bound to human left ventricle with a K(D) value of 0.35+/-0.08 nM, B(max) of 4.3+/-0.9 fmol mg(-1) protein with a Hill slope of 0.97+/-0.04 and to the right atria with a K(D) of 0.33+/-0.09 nM, B(max) of 3.1+/-0.6 fmol mg(-1) protein and a Hill slope of 0.93+/-0.05. 4. [(125)I]-(Pyr(1))Apelin-13 binding sites were localized using autoradiography to human cardiovascular tissue, including coronary artery, aorta and saphenous vein grafts. In rat tissue a high density of receptors were localized to the molecular layer of the rat cerebellum, rat lung, rat heart and low levels in the rat kidney cortex. 2. (Pyr(1))Apelin-13 potently contracted human saphenous vein with a pD(2) value of 8.4+/-0.2 (n=8). The maximum response elicited by the peptide was 22.6+/-6% of 100 mM KCl. 6. We provide the first evidence of APJ receptor expression, relative densities and functional properties of (Pyr(1))Apelin-13 in human cardiovascular tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250876      PMCID: PMC1572672          DOI: 10.1038/sj.bjp.0703939

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Differential distribution of endothelin peptides and receptors in human adrenal gland.

Authors:  A P Davenport; S L Hoskins; R E Kuc; C Plumpton
Journal:  Histochem J       Date:  1996-11

2.  Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin.

Authors:  M Hosoya; Y Kawamata; S Fukusumi; R Fujii; Y Habata; S Hinuma; C Kitada; S Honda; T Kurokawa; H Onda; O Nishimura; M Fujino
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

3.  Characterization of apelin, the ligand for the APJ receptor.

Authors:  D K Lee; R Cheng; T Nguyen; T Fan; A P Kariyawasam; Y Liu; D H Osmond; S R George; B F O'Dowd
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

4.  A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11.

Authors:  B F O'Dowd; M Heiber; A Chan; H H Heng; L C Tsui; J L Kennedy; X Shi; A Petronis; S R George; T Nguyen
Journal:  Gene       Date:  1993-12-22       Impact factor: 3.688

5.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

6.  Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues.

Authors:  A M O'Carroll; T L Selby; M Palkovits; S J Lolait
Journal:  Biochim Biophys Acta       Date:  2000-06-21

7.  Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

8.  Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.

Authors:  K Tatemoto; M Hosoya; Y Habata; R Fujii; T Kakegawa; M X Zou; Y Kawamata; S Fukusumi; S Hinuma; C Kitada; T Kurokawa; H Onda; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

9.  Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium.

Authors:  P Molenaar; G O'Reilly; A Sharkey; R E Kuc; D P Harding; C Plumpton; G A Gresham; A P Davenport
Journal:  Circ Res       Date:  1993-03       Impact factor: 17.367

10.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

Authors:  A P Davenport; G O'Reilly; R E Kuc
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

View more
  52 in total

1.  Modulation of the apelin/APJ system in heart failure and atherosclerosis in man.

Authors:  Sarah L Pitkin; Janet J Maguire; Rhoda E Kuc; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Upregulation of the apelin-APJ pathway promotes neointima formation in the carotid ligation model in mouse.

Authors:  Yoko Kojima; Ramendra K Kundu; Christopher M Cox; Nicholas J Leeper; Joshua A Anderson; Hyung J Chun; Ziad A Ali; Euan A Ashley; Paul A Krieg; Thomas Quertermous
Journal:  Cardiovasc Res       Date:  2010-02-22       Impact factor: 10.787

3.  Apelin Reduces Nitric Oxide-Induced Relaxation of Cerebral Arteries by Inhibiting Activation of Large-Conductance, Calcium-Activated K Channels.

Authors:  Amreen Mughal; Chengwen Sun; Stephen T OʼRourke
Journal:  J Cardiovasc Pharmacol       Date:  2018-04       Impact factor: 3.105

4.  Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.

Authors:  Gerry T M Wagenaar; Rozemarijn M A Sengers; El Houari Laghmani; Xueyu Chen; Melissa P H A Lindeboom; Anton J M Roks; Gert Folkerts; Frans J Walther
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

5.  Apela Regulates Fluid Homeostasis by Binding to the APJ Receptor to Activate Gi Signaling.

Authors:  Cheng Deng; Haidi Chen; Na Yang; Yi Feng; Aaron J W Hsueh
Journal:  J Biol Chem       Date:  2015-05-20       Impact factor: 5.157

6.  Apelin attenuates hyperoxic lung and heart injury in neonatal rats.

Authors:  Yvonne P de Visser; Frans J Walther; El Houari Laghmani; Arnoud van der Laarse; Gerry T M Wagenaar
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

7.  Apelin attenuates UVB-induced edema and inflammation by promoting vessel function.

Authors:  Mika Sawane; Hiroyasu Kidoya; Fumitaka Muramatsu; Nobuyuki Takakura; Kentaro Kajiya
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

8.  HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes.

Authors:  Alexander J Glassford; Patrick Yue; Ahmad Y Sheikh; Hyung J Chun; Shirin Zarafshar; Denise A Chan; Gerald M Reaven; Thomas Quertermous; Philip S Tsao
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-18       Impact factor: 4.310

9.  CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2004-09-20       Impact factor: 8.739

10.  Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis.

Authors:  Hiroyasu Kidoya; Masaya Ueno; Yoshihiro Yamada; Naoki Mochizuki; Mitsugu Nakata; Takashi Yano; Ryo Fujii; Nobuyuki Takakura
Journal:  EMBO J       Date:  2008-01-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.